BioXcel Therapeutics Announces First Patient Enrolled in Phase 1b/2 Study of BXCL501 for Acute Treatment of Agitation Associated with Dementia
January 07, 2020 07:00 ET
|
BioXcel Therapeutics
Foundational study with plans to address multiple types of agitation associated with dementia Expands the potential therapeutic use of BXCL501 beyond neuropsychiatric disorders Topline...
BioXcel Therapeutics Announces Initiation of Pivotal Phase 3 Studies of BXCL501 for Acute Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorder
December 30, 2019 07:00 ET
|
BioXcel Therapeutics
NEW HAVEN, Conn., Dec. 30, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches...
BioXcel Therapeutics to Expand Study of BXCL701 into Multiple Advanced Solid Tumor Types
December 11, 2019 07:00 ET
|
BioXcel Therapeutics
NEW HAVEN, Conn., Dec. 11, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence...
BioXcel Therapeutics Prepares to Initiate Pivotal Phase 3 Studies with BXCL501 Following Positive End-of-Phase 2 Meeting with FDA
December 03, 2019 07:00 ET
|
BioXcel Therapeutics
The Company plans to initiate the pivotal studies by year end, with topline data reported mid-2020 The first sublingual, non-invasive acute treatment candidate designed for agitation in...